A prospective trial showing the safety of adjusted-dose enoxaparin for thromboprophylaxis of pregnant women with mechanical prosthetic heart valves

34Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Objective: To determine whether dosage adjustment of enoxaparin during pregnancy, to maintain a peak anti-Xa of 1.0 to 1.2 U/mL, is safe for women with mechanical prosthetic heart valves (MPHV). Design: A prospective observational study. Setting: This study was performed at Charlotte Maxeke Johannesburg Academic Hospital from 2007 to 2009. Population: Fifteen women with MPHVs. Methods: Women were treated with enoxaparin with dosage adjustment to achieve a peak anti-Xa of 1.0 to 1.2 U/ mL. Main Outcome Measures: Main outcomes measured were prosthetic valve thrombosis, bleeding, and maternal mortality. Results: There was no maternal mortality. None of the women developed valvular thrombosis during pregnancy. In all, 2 women developed epistaxis and another developed spotting per vaginum. Conclusion: Our data show that enoxaparin may be administered safely during pregnancy to pregnant women with MPHV when there is dosage adjustment throughout pregnancy to maintain an anti-Xa of 1.0 to 1.2 U/mL. © The Author(s) 2011.

Cite

CITATION STYLE

APA

Saeed, C. R., Frank, J. B., Pravin, M., Aziz, R. H., Serasheini, M., & Gabrielle Dominique, T. (2011, August). A prospective trial showing the safety of adjusted-dose enoxaparin for thromboprophylaxis of pregnant women with mechanical prosthetic heart valves. Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/1076029610371470

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free